No Data
No Data
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares
Mineralys Therapeutics Price Target Announced at $30.00/Share by HC Wainwright & Co.
Mineralys Therapeutics Price Target Announced at $30.00/Share by HC Wainwright & Co.
Mineralys Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 132.74% HC Wainwright & Co. → $30 Initiates Coverage On → Buy 04/02/2024 132.74% Goldman
H.C. Wainwright Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $30
H.C. Wainwright analyst Matthew Caufield initiates coverage on $Mineralys Therapeutics(MLYS.US)$ with a buy rating, and sets the target price at $30.According to TipRanks data, the analyst has a
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat